{"id":"bms-986278","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Gastrointestinal disorders"}]},"_chembl":{"chemblId":"CHEMBL4303322","moleculeType":"Small molecule","molecularWeight":"518.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The NLRP3 inflammasome is a multi-protein complex that activates caspase-1, leading to the production of pro-inflammatory cytokines IL-1β and IL-18. By selectively inhibiting NLRP3, BMS-986278 dampens pathological inflammation without broadly suppressing immune function. This mechanism is relevant to inflammatory and autoinflammatory diseases where NLRP3 activation drives disease pathology.","oneSentence":"BMS-986278 is a selective inhibitor of the NLRP3 inflammasome that reduces excessive inflammatory responses by blocking a key protein complex involved in innate immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:43.639Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT06003426","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-09-14","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":1255},{"nctId":"NCT06025578","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-10-25","conditions":"Progressive Pulmonary Fibrosis","enrollment":1057},{"nctId":"NCT07422298","phase":"PHASE1","title":"A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-02-19","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT07441408","phase":"PHASE3","title":"Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-12-16","conditions":"Pulmonary Fibrosis","enrollment":2277},{"nctId":"NCT04308681","phase":"PHASE2","title":"A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-07-29","conditions":"Pulmonary Fibrosis","enrollment":403},{"nctId":"NCT06723535","phase":"PHASE1","title":"A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2024-12-07","conditions":"Kidney Failure, Chronic, Healthy Volunteers, Renal Impairment","enrollment":27},{"nctId":"NCT06746402","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-02-10","conditions":"Healthy Volunteers","enrollment":42},{"nctId":"NCT06715683","phase":"PHASE1","title":"A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2024-12-12","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT06568458","phase":"PHASE1","title":"A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2024-09-19","conditions":"Healthy Participants","enrollment":71},{"nctId":"NCT06425198","phase":"PHASE1","title":"Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2024-06-10","conditions":"Hepatic Impairment, Healthy Participants","enrollment":37},{"nctId":"NCT05985590","phase":"PHASE1","title":"A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-08-18","conditions":"Healthy Volunteers","enrollment":37},{"nctId":"NCT05932303","phase":"PHASE1","title":"A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-07-12","conditions":"Healthy Participants","enrollment":47},{"nctId":"NCT05805904","phase":"PHASE1","title":"A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-03-29","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT05684289","phase":"PHASE1","title":"A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-01-03","conditions":"Healthy Participants","enrollment":61},{"nctId":"NCT04567667","phase":"PHASE1","title":"Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-10-15","conditions":"Healthy Volunteers","enrollment":9},{"nctId":"NCT04468815","phase":"PHASE1","title":"A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2020-07-10","conditions":"Healthy Participants","enrollment":24},{"nctId":"NCT03981094","phase":"PHASE1","title":"A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-05-10","conditions":"Idiopathic Pulmonary Fibrosis (IPF)","enrollment":22},{"nctId":"NCT03429933","phase":"PHASE1","title":"A Study of Experimental Medication BMS-986278 Given to Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-02-07","conditions":"Healthy Participants","enrollment":112},{"nctId":"NCT03712540","phase":"PHASE1","title":"An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-09-06","conditions":"Healthy Participants","enrollment":39}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CYSTITIS"},{"count":1,"reaction":"HAEMATURIA"},{"count":1,"reaction":"IDIOPATHIC PULMONARY FIBROSIS"},{"count":1,"reaction":"LOWER URINARY TRACT SYMPTOMS"},{"count":1,"reaction":"URINARY TRACT INFECTION"}],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Admilparant"],"phase":"phase_3","status":"active","brandName":"BMS-986278","genericName":"BMS-986278","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BMS-986278 is a selective inhibitor of the NLRP3 inflammasome that reduces excessive inflammatory responses by blocking a key protein complex involved in innate immunity. Used for Acute coronary syndrome, Chronic kidney disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":7,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}